Ji Hyun Youk MD, Presenter: Nothing to Disclose

Inkyung Jung, Abstract Co-Author: Nothing to Disclose

Eun-Kyung Kim, Abstract Co-Author: Nothing to Disclose

Min Jung Kim MD, Abstract Co-Author: Nothing to Disclose

Hee Jung Moon MD, Abstract Co-Author: Nothing to Disclose

Eun Ju Son MD, PhD, Abstract Co-Author: Nothing to Disclose

To determine follow-up protocol of breast US in concordant benign lesions after US-guided 14-gauge core needle breast biopsy (CNB)

The result of imaging-pathology correlation and postbiopsy management after 3888 US-guided 14-gauge CNBs performed between August 2005 and March 2008 was reviewed from our database. Of 2314 concordant benign results, a total of 1492 lesions in 1309 patients having follow-up breast US were assessed for the results of follow-up US and repeat biopsy. The CNB results dichotomized as nonspecific or specific diagnosis and the associated symptom presented were noted. The rate of lesion progression detected and positive predictive values (PPVs) for detecting malignancy at each follow-up interval were calculated and compared by using Fisher’s exact test.

In 1492 lesions with follow-up US (mean, 27.7 months; range, 1.6-62.5 months; mean, 2.7 times; range, 1-8 times), ten malignancies (0.7%) were found at repeat biopsy. The rates of lesion progression at US were 3.2% (33 of 1029), 2.6% (7 of 267), and 5.1% (10 of 196) at 6-months, 12-months, and long-term follow-up intervals, respectively (p=0.32). The rates of malignancy detected at initial follow-up US were 66.7% (4 of 6), 0% (0 of 1), 100% (3 of 3) at 6-months, 12-months, and long-term follow-up intervals, respectively (p=0.16). The PPVs were 12.1% (4 of 33), 0% (0 of 7), and 30.0% (3 of 10) at 6-months, 12-months, and long-term follow-up intervals, respectively (p=0.22). When the results were dichotomized as nonspecific (p=0.29) or specific CNB result (p=0.33) and as symptomatic (p=0.49) or asymptomatic (p=0.09) cases, there were no significant differences in the rates of malignancy.

The rates of lesion progression at US and the PPVs were not significantly different among 6-months, 12-months, and long-term follow-up intervals, although those at 6-months follow-up interval were higher than at 12-months follow-up interval.

Short-term follow-up US after benign concordant result at US-guided 14-gauge CNB may not contribute to improving breast cancer diagnosis.

Youk, J, Jung, I, Kim, E, Kim, M, Moon, H, Son, E, US Follow-up Protocol in Concordant Benign Result after US-guided 14-gauge Core Needle Breast Biopsy.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11034527.html